Lumakras (sotorasib) / Amgen 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 


«12...2324252627282930313233...3839»
  • ||||||||||  adagrasib (MRTX849) / Mirati, Lumakras (sotorasib) / Amgen
    Clinical, Journal:  Prognostic impact of KRAS G12C mutation in patients with NSCLC: results from the ETOP Lungscape Project. (Pubmed Central) -  Jul 9, 2021   
    Updated safety and efficacy data will be presented.). In this large, clinically annotated stage I-III NSCLC cohort, the specific Kr_G12C mutation is significantly associated with poorer prognosis (adjusting for clinicopathological characteristics) among adenocarcinomas as well as in unselected NSCLCs.
  • ||||||||||  Lumakras (sotorasib) / Amgen
    Clinical Trial,Phase II, Journal, Tumor Mutational Burden, PD(L)-1 Biomarker, IO biomarker:  Sotorasib for Lung Cancers with KRAS p.G12C Mutation. (Pubmed Central) -  Jul 9, 2021   
    P1/2
    In this phase 2 trial, sotorasib therapy led to a durable clinical benefit without new safety signals in patients with previously treated KRAS p.G12C-mutated NSCLC. (Funded by Amgen and the National Institutes of Health; CodeBreaK100 ClinicalTrials.gov number, NCT03600883.).
  • ||||||||||  adagrasib (MRTX849) / Mirati, Lumakras (sotorasib) / Amgen
    Preclinical, Journal:  Acquired Resistance to KRAS Inhibition in Cancer. (Pubmed Central) -  Jul 9, 2021   
    P1/2
    Diverse genomic and histologic mechanisms impart resistance to covalent KRAS inhibitors, and new therapeutic strategies are required to delay and overcome this drug resistance in patients with cancer. (Funded by Mirati Therapeutics and others; ClinicalTrials.gov number, NCT03785249.).
  • ||||||||||  Lumakras (sotorasib) / Amgen
    FDA event, Journal, PD(L)-1 Biomarker, IO biomarker:  FDA Approves First KRAS Inhibitor: Sotorasib. (Pubmed Central) -  Jun 24, 2021   
    The FDA has approved the first KRAS-targeted therapy, sotorasib, for patients with previously treated non-small cell lung cancer with KRASG12C mutations. In a phase II trial, the drug yielded a median progression-free survival of 6.8 months in patients whose disease had advanced despite treatment with standard therapies, namely platinum-based chemotherapy and PD-1-PD-L1 inhibitors.
  • ||||||||||  Lumakras (sotorasib) / Amgen
    Journal:  Sotorasib Is Active in KRAS-Mutant Non-Small Cell Lung Cancer. (Pubmed Central) -  Jun 22, 2021   
    Our understanding of the etiology of the rat specific renal toxicity informs the translational risk assessment for patients. Sotorasib produced objective responses in 37.1% of patients for a median duration of 11.1 months.
  • ||||||||||  inlexisertib (DCC-3116) / Ono Pharma
    Enrollment open, Combination therapy, Monotherapy, Metastases:  A Phase 1/2 Study of DCC-3116 in Patients With RAS/MAPK Pathway Mutant Solid Tumors (clinicaltrials.gov) -  Jun 18, 2021   
    P1,  N=130, Recruiting, 
    Sotorasib produced objective responses in 37.1% of patients for a median duration of 11.1 months. Not yet recruiting --> Recruiting
  • ||||||||||  Lumakras (sotorasib) / Amgen
    Trial completion date, Trial primary completion date, Monotherapy, IO biomarker:  CodeBreak101: Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101) (clinicaltrials.gov) -  Jun 7, 2021   
    P1b/2,  N=1113, Recruiting, 
    The current study suggested that AMG510 may have potential clinical use in combination with MEK and BCL-XL inhibitors in the treatment of patients with colorectal cancer exhibiting the G12C KRAS mutation. Trial completion date: Nov 2025 --> Feb 2028 | Trial primary completion date: Jun 2023 --> Jan 2024